Who we are and what we do

We are a team of professionals with long time experience of in-vivo pharmacology and toxicology. We assist pharmaceutical companies in their endeavours to find cures for diseases for which there are no effective treatments today and those who are working to improve the effectiveness of discovered drugs.

How we work

Together with the customer we develop a project plan. Depending on the challenge Adlego Biomedical either runs projects solitary or puts together a group of experts from our network to manage complex projects. Therefore, we can be cost effective and produce with the highest quality a variety of studies from standard DMPK studies to demanding effect studies and large toxicity studies.

Why are preclinical studies needed?

To enter into clinical trials pharmaceutical companies need to demonstrate to regulatory agencies that a new drug is effective and relatively safe to administer to humans. Information about interactions between a new drug and a living organism is obtained with use of preclinical methods.

Focus

Our main focus is to establish long-term collaboration with drug developing companies that are early in their development of new candidate drugs. With this approach we establish a relationship that is fruitful for both parties when disease models need to be developed to show proof-of-concept, and when DMPK and toxicity data are gathered. Since we are working with experts within the various fields of drug development and document all studies according to GLP the customer is guaranteed top quality reports, which fulfil the requirements of regulatory bodies. 79334397-258x120

Case

Although we have been working with many models of cancer we continue to get requests for models we have not used before. Before we use a new model in proof-of-concept studies we validate it to obtain information about growth rate and to show that the tumour is sensitive to current therapies. We commonly also use histological techniques to further analyze the effect of therapies. Here is an example from the validation of the ACHN tumour model: Bild31

Latest News

Invitation to LÄKEMEDELSEVENTET 2015!

Adlego would like to invite you to a exciting afternoon at the the Läkemedelseventet 2015, which is to be held on 22nd April at 14.00 in Grev Turegatan 16 (IVA), Stockholm. We look forward to seeing you...

read more

Our start to 2015!

As usual, the beginning of year 2015 has been busy catching up with documentation and finalising reports from the studies performed at end of the 2014.  We were also very busy with a number of PK studies in rabbits of a well-known drug which is now to be developed for...

read more

Adlego to partner at Life Science Management Day 2015

Adlego Biomedical are looking forward to being partners and taking part of the Life Science Management Day 2015 which is to be held on 5th November in Stockholm, Sweden. The seminar is looking at what is needed to be successful in life sciences and that luck can play...

read more

Lucy Robertshaw to present at Sorainen Business Breakfast

Lucy Robertshaw will be presenting at the Sorainen business breakfast, which is being held in Lithuania on the 5th February. Patent protection for inventions in Life Sciences is complicated by territorial differences with respect to what technology is eligible for...

read more

Latest Publications

In vivo electroporation

The mechanisms by which in vivo electroporation (EP) improves the potency of i.m. DNA vaccination were characterized by using the hepatitis C virus nonstructural (NS) 3/4A gene. Following a standard i.m. injection of DNA with or without in vivo EP, plasmid levels...

read more

Interesting Reading